Oxford Biomedica PLC Director Dealings (4830A)
September 29 2020 - 9:51AM
UK Regulatory
TIDMOXB
RNS Number : 4830A
Oxford Biomedica PLC
29 September 2020
Director Dealings
Oxford, UK - 29 September 2020: Oxford Biomedica plc ("Oxford
Biomedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that Vulpes Life Sciences Fund
("Vulpes"), whose portfolio manager Martin Diggle is a
Non-Executive Director on the Board of Oxford Biomedica, has
entered into a pledge of security of 750,000 ordinary shares
("Transferred Shares") in connection with a financing transaction
in the normal course of business for Vulpes.
Vulpes is required to redeem the Transferred Shares at maturity
when the loan is repaid at the end of the three year term.
Following this transaction Vulpes Testudo/Vulpes Life Sciences
Fund holds 10,713,616 ordinary shares representing 13.0% of the
Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
transaction in number of Ordinary Shares.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Vulpes Life Sciences Fund
2. Reason for the notification
a. Position/status Martin Diggle, Non-Executive Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford Biomedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Pledge of ordinary shares as a security
transaction in relation to a corporate loan
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
NA 750,000
e. Aggregated information 750,000
* Aggregated volume NA
NA
* Price
* Aggregated total
f. Date of the transaction 2020-09-25
g. Place of the transaction Outside of a trading venue
The issued share capital of the Group is 82,223,225 ordinary 50p
shares.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen,
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy
Consortium and Imperial Innovations, through which it has long-term
economic interests in other potential gene and cell therapy
products. Additionally the group has signed a Clinical and
Commercial Supply Agreement with AstraZeneca for manufacture of the
adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica
is based across several locations in Oxfordshire, UK and employs
more than 580 people. Further information is available at
www.oxb.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPURCBUPUGCB
(END) Dow Jones Newswires
September 29, 2020 10:51 ET (14:51 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024